CompletedNCT02670551
Cariprazine for Bipolar I Depression: Study 2
About this title
Read the official source — NCT02670551Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 73 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: March 17, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 488
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Estonia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02670551
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Costa Mesa, United States · Escondido, United States
61 more locations
- Glendale, United States
- Long Beach, United States
- Oakland, United States
- San Diego, United States
- Sherman Oaks, United States
- Temecula, United States
- Upland, United States
- Norwich, United States
- Jacksonville, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Smyrna, United States
- Skokie, United States
- Winfield, United States
- Saint Charles, United States
- Las Vegas, United States
- Berlin, United States
- Cedarhurst, United States
- New York, United States
- Canton, United States
- Cincinnati, United States
- Columbus, United States
- Dayton, United States
- Oklahoma City, United States
- Portland, United States
- Salem, United States
- Allentown, United States
- Lincoln, United States
- Memphis, United States
- Houston, United States
- Plano, United States
- The Woodlands, United States
- Richmond, United States
- Bellevue, United States
- Kirkland, United States
- Seattle, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Tallinn, Estonia
- Tartu, Estonia
- Kaunas, Lithuania
- Vilnius, Lithuania
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Leszno, Poland
- Lublin, Poland
- Pruszcz Gdański, Poland
- Torun, Poland
- San Juan, Puerto Rico
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
